U.S. FDA Clears Biosimilar for Eye Conditions

The U.S. Food and Drug Administration has approved Ranluspec, a biosimilar referencing Lucentis, for treating various retinal diseases. This medication is notable for being the first interchangeable ranibizumab biosimilar available in both vial and pre-filled syringe forms. This development could enhance patient access and potentially reduce treatment costs for these eye conditions.